← Back to headlines
Eli Lilly Price Target Raised After FDA Approval for Fundayo
Eli Lilly and Company (LLY) saw its price target raised by analysts following the FDA's approval of its new drug, Fundayo.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
US-Canada Trade Tensions Drive Up Prices and Spark Canadian Boycotts
18m ago
DMG Blockchain Solutions Reports Third-Quarter Financial Results
49m ago
SoftBank in Talks to Buy Majority Stake in Humanoid Robotics Startup 1X
50m ago
Raymond James Financial Announces Quarterly Dividend of $0.54 Per Share
1h ago